HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, February 11 /PRNewswire/ --
- Strategic Position Created to Increase Pharmaceutical Biotechnology Partnerships
Agendia, a world leader in molecular cancer diagnostics, today announced the appointment of Alan B. Carter as the company's new Vice President of Global Business Development.
As we continue to grow as a global company, Alan's appointment furthers one of our primary aims, commented Dr. Bernhard Sixt, Ph.D., President and Chief Executive Officer. His extensive business development expertise will strengthen our ongoing programs and pipeline projects and also allows us to capitalize on our genomics platform in close collaboration with biotechnology and pharmaceutical partners. With Alan's involvement, Agendia will continue to play a central role in making targeted therapies one of the cornerstones of personalized medicine.
Mr. Carter brings 25 years of business development, sales and marketing experience from a number of top tier life sciences companies such as BioTrove, Celera, Applied Biosystems and Perkin Elmer. At Agendia, Mr. Carter will assume responsibility for strategic business opportunities to build on the current success of Agendia's molecular diagnostics portfolio. This products suite includes MammaPrint(R), the only FDA approved test for rapidly and accurately diagnosing therapeutic options for breast cancer patients. Additionally, he will play an important role in forging Agendia's strategic alliances with pharmaceutical and biotech companies to accelerate the use of molecular diagnostics in drug development, companion diagnostics and safety testing programs.
About Agendia
Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.
For more information please visit http://www.agendia.com.
MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 (Office), +31-620-083-509 (Mobile), hans.herklots@agendia.com; Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 (Office), +1-917-975-3191 (Mobile), vdelva@ricochetpr.com
Comments